Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. United Therapeutics's annualizedNet Income for the quarter that ended in Dec. 2023 was $868 Mil. United Therapeutics's average total tangible assets for the quarter that ended in Dec. 2023 was $7,016 Mil. Therefore, United Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 12.38%.
The historical rank and industry rank for United Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
UTHR'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2.99 Med: 15.7 Max: 32.49
Current: 14.93
During the past 13 years, United Therapeutics's highest Return-on-Tangible-Asset was 32.49%. The lowest was -2.99%. And the median was 15.70%.
UTHR's Return-on-Tangible-Asset is ranked better than 95.88% of 1555
companies
in the Biotechnology industry
Industry Median: -40.28
vs UTHR: 14.93
United Therapeutics Return-on-Tangible-Asset Historical Data
The historical data trend for United Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, United Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Return-on-Tangible-Asset Distribution
For the Biotechnology industry and Healthcare sector, United Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Return-on-Tangible-Asset falls into.
United Therapeutics Return-on-Tangible-Asset Calculation
United Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2023) net income data.
United Therapeutics (NAS:UTHR) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
United Therapeutics Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of United Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics (United Therapeutics) Business Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UTHR has been successfully added to your 